12/22
04:01 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
12/16
05:43 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) was upgraded by analysts at Sanford C. Bernstein to a "strong-buy" rating.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) was upgraded by analysts at Sanford C. Bernstein to a "strong-buy" rating.
12/15
03:46 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Leerink Partners from $75.00 to $86.00. They now have an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Leerink Partners from $75.00 to $86.00. They now have an "outperform" rating on the stock.
12/12
11:33 am
bbio
What Recent Clinical Wins Mean For BridgeBio Pharma's Evolving Growth Story [Yahoo! Finance]
Low
Report
What Recent Clinical Wins Mean For BridgeBio Pharma's Evolving Growth Story [Yahoo! Finance]
12/11
02:03 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) is now covered by analysts at Sanford C. Bernstein. They set an "outperform" rating on the stock.
11/25
07:30 am
bbio
BridgeBio to Participate in December Investor Conferences
Low
Report
BridgeBio to Participate in December Investor Conferences
11/19
04:01 pm
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
11/11
09:44 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $76.00 to $84.00. They now have an "overweight" rating on the stock.
Medium
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Wells Fargo & Company from $76.00 to $84.00. They now have an "overweight" rating on the stock.
11/10
08:23 pm
bbio
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
Medium
Report
BridgeBio Pharma, Inc. (BBIO) Presents at UBS Global Healthcare Conference 2025 Transcript [Seeking Alpha]
11/10
10:38 am
bbio
AbCellera Appoints Dr. Stephen Quake to its Board of Directors [Yahoo! Finance]
Low
Report
AbCellera Appoints Dr. Stephen Quake to its Board of Directors [Yahoo! Finance]
11/8
10:55 am
bbio
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations [Yahoo! Finance]
Low
Report
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations [Yahoo! Finance]
11/8
10:41 am
bbio
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
Low
Report
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
11/7
03:02 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at JPMorgan Chase & Co. from $76.00 to $77.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at JPMorgan Chase & Co. from $76.00 to $77.00. They now have an "overweight" rating on the stock.
11/4
08:40 pm
bbio
BridgeBio Pharma Inc (BBIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Inc (BBIO) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ... [Yahoo! Finance]
11/4
07:30 am
bbio
BridgeBio to Participate in November Investor Conferences
Low
Report
BridgeBio to Participate in November Investor Conferences
11/3
08:03 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
11/3
07:30 am
bbio
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
Low
Report
BridgeBio to Present Data from the Overall ATTR-CM Variant and V142I (V122I) Populations from ATTRibute-CM at the AHA Scientific Sessions 2025
10/30
04:14 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at TD Cowen from $60.00 to $95.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at TD Cowen from $60.00 to $95.00. They now have a "buy" rating on the stock.
10/30
12:05 pm
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "positive" rating reaffirmed by analysts at Cowen Inc.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "positive" rating reaffirmed by analysts at Cowen Inc.
10/30
10:40 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $71.00 price target on the stock, up previously from $69.00.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "outperform" rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $71.00 price target on the stock, up previously from $69.00.
10/30
09:46 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Piper Sandler from $93.00 to $98.00. They now have an "overweight" rating on the stock.
Medium
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Piper Sandler from $93.00 to $98.00. They now have an "overweight" rating on the stock.
10/30
09:46 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Cantor Fitzgerald from $100.00 to $110.00. They now have an "overweight" rating on the stock.
Medium
Report
BridgeBio Pharma (NASDAQ:BBIO) had its price target raised by analysts at Cantor Fitzgerald from $100.00 to $110.00. They now have an "overweight" rating on the stock.
10/30
08:41 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $80.00 price target on the stock, up previously from $66.00.
Low
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at Truist Financial Corporation. They now have a $80.00 price target on the stock, up previously from $66.00.
10/30
08:14 am
bbio
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
BridgeBio Pharma (NASDAQ:BBIO) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
10/29
04:01 pm
bbio
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates
Medium
Report
BridgeBio Reports Third Quarter 2025 Financial Results and Business Updates